Phase 2 N=93 A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 48 in the PANSS Total Score — -38.5 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
Phase 3 N=386 To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia
Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses
Phase 1 N=37 A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Abbreviated Extrapyramidal Symptom Rating Scale (ESRS-A) Scores (Cohorts 1 and 2) at Day 10 — -0.2; -0.3; 0.1; 0.0 Units on a scale
Phase 1 N=39 Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
Schizophrenia
Primary: Maximum Observed Plasma Concentration (Cmax) (Single Dose) — 1.920; 3.830 nanograms per milliliter (ng/mL)
Phase 3 N=305 A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation — 153; 77; 16; 0 Participants
Phase 3 N=478 A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Schizophrenia
Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 51; 190 participants
Phase 3 N=248 Long-Term Study of MP-214 in Patients With Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 67; 92; 50 Participants
Phase 3 N=629 Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Number of Participants With Adverse Events. — 395; 189 participants
Phase 3 N=200 Long-term Study of DSP-5423P in Patients With Schizophrenia
Schizophrenia
Primary: Adverse Events and Adverse Drug Reactions, Etc. — 82; 92; 174; 60 Participants
Phase 2 N=61 A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
Schizophrenia
Primary: Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study — 59 participants
N/A N=88 Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30
Phase 3 N=500 Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
Schizophrenia
Primary: Participants With Treatment-Emergent Adverse Events (TEAE) — 306; 21; 22; 18 Participants
Phase 3 N=239 Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
Schizophrenia
Primary: Percentage of Participants With Adverse Events (AEs) — 60.2; 56.4; 65.2; 60.5 percentage of participants
Phase 3 N=42 A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 42 Participants
Phase 4 N=305 Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
Schizophrenia · Schizoaffective Disorder
Primary: Substantial Clinical Deterioration Measured by Psychotic Symptoms — 1.8; 2.0 units on a scale
Phase 3 N=125 A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 78; 42 Participants
Phase 4 N=40 An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score at Week 96 — 73.00; 18.24 Units on a scale
Phase 4 N=24 Lurasidone Effects on Tissue Glutamate in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Cerebral Glutamate Levels — -1.434662171; -1.933853656; -1.412294235; -1.838991525 relative unit (RU as compared to water)
Phase 4 N=450 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
Schizophrenia
Primary: Time to First Treatment Failure — 416; 226 Days
Phase 4 N=133 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13 — 88.98; 22.468 units on a scale
N/A N=63 Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia
Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale
Phase 3 N=633 Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Schizophrenia
Primary: Time to Exacerbation of Psychotic Symptoms/Impending Relapse — NA; 209 Days — p=<0.0001
Phase 3 N=228 A Long-Term Study of JNS007ER in Patients With Schizophrenia
Schizophrenia
Primary: Incidence of Adverse Events — 97.4 percentage of patients
Phase 4 N=299 An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 24 — 72.4; -6.9 Units on a scale
Phase 3 N=676 PEARL Schizophrenia Maintenance
Schizophrenia
Primary: Time to First Relapse Event During Double-blind Phase — NA; 192 days — p=0.039
Phase 3 N=323 An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…
Phase 3 N=523 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Schizophrenia · Schizophreniform Disorder · Bipolar I Disorder
Primary: Incidence of Adverse Events — 314 Participants
Phase 3 N=282 A Long-term Trial of OPC-34712 in Patients With Schizophrenia
Schizophrenia
Primary: Percentage of Participants With Adverse Events — 156; 79; 95; 38 Participants
Phase 2 N=98 Safety and Tolerability Study of Drug to Treat Schizophrenia
Schizophrenia
Primary: Number of Participants With Adverse Events — 19; 22; 18 participants